Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sublocade Clear all
Suspended No phase listed Observational Accepts healthy volunteers

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

NCT05121428
View directory record Official record
Conditions
Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 24, 2026, 1:47 PM EDT
Completed No phase listed Observational

Fetal Neurobehavior in Poly-drug Dependent Women

NCT00653692
View directory record Official record
Conditions
Poly Drug Exposed Pregnancies
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 24, 2026, 1:47 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

NCT03616236
View directory record Official record
Conditions
Opioid Use
Interventions
Buprenorphine/Naloxone, Treatment as usual
Drug · Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 24, 2026, 1:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

BRIDGE Device for Treatment of Opioid Withdrawal

NCT04162145
View directory record Official record
Conditions
Opioid Withdrawal, Pain, Craving
Interventions
Active BRIDGE device placement, Inactive BRIDGE device placement
Device
Lead sponsor
BrightView LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 24, 2026, 1:47 PM EDT
Terminated Phase 2 Interventional Results available

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD

NCT03852628
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Abuse
Interventions
2mg Buprenex and 380mg Vivitrol, Placebo (SL pill qd, IM injection q4weeks)
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

NCT00158236
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine, Buprenorphine and Naloxone, Hydromorphone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 1998
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 24, 2026, 1:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder

NCT03745339
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

NCT03492099
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Phase 2 Interventional

Buprenorphine Pharmacology Related to Addiction Treatment - 18

NCT00000236
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 24, 2026, 1:47 PM EDT
Terminated Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

NCT01135524
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
89
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairfield, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 24, 2026, 1:47 PM EDT
Recruiting Not applicable Interventional

Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder

NCT06827288
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
SUN, SUN + Telebridge, ED-ITT, ED-ITT + BHS
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 24, 2026, 1:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Social Functioning in Opioid Use Disorder

NCT07044466
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CBT4CBT-Buprenorphine
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 1:47 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Phase 3 Interventional Results available

Long-term Open-Label Safety Study to Evaluate EN3409

NCT01755546
View directory record Official record
Conditions
Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions
EN3409
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 24, 2026, 1:47 PM EDT
Terminated Phase 3 Interventional Results available

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

NCT01125917
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

NCT04982627
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions
BNI Chatbot, OUD Education & Treatment Resources
Behavioral
Lead sponsor
Center for Progressive Recovery, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 24, 2026, 1:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 1:47 PM EDT
Completed No phase listed Observational

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243
View directory record Official record
Conditions
Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
Interventions
MET/CBT based individualized counseling, Buprenorphine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 24, 2026, 1:47 PM EDT
Withdrawn Phase 4 Interventional

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

NCT04771689
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 24, 2026, 1:47 PM EDT
Terminated Phase 3 Interventional

Study of Probuphine in Patients With Opioid Dependence

NCT00772785
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 24, 2026, 1:47 PM EDT
Completed Not applicable Interventional

An App to Aid in Transitioning Off Opioid Medication

NCT03077932
View directory record Official record
Conditions
Opiate Use Disorder, Opiate Withdrawal Syndrome
Interventions
App Development and Open Pilot
Other
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 24, 2026, 1:47 PM EDT